This study was conducted to explore the effect of adipose-derived stem cells (ASCs) on the graft survival rates of fat particles in rabbits. Six domestic rabbits were used for a 3-month study; 1.4 grams of fat tissues were harvested from the bilateral inguinal regions of each animal. They were cut into granules and divided into three parts (A = 0.4 g, B = 0.4 g, and C = 0.6 g). Part A was centrifuged after 0.075% collagenase digestion for isolation of the stromal vascular fraction (SVF). About 0.2 grams of SVF containing ASCs was obtained, and then incorporated with part B to create a treated group, whereas part C was treated as a control group. The tissues in both groups were randomly transplanted into a subcutaneous space that had been created on each side of the dorsal midline of the rabbit. The grafts were taken out after 3 months for calculation of the survival rates. The graft survival rate in the treated group was 23.56 ± 2.49%, while that in the control group was 11.06 ± 2.10%. The graft survival rate in the treated group increased significantly, compared with in the control group (p < 0.01). Improved transplantation effects may be obtained by implanting the fat particles mixed with ASCs. It is suggested that this approach has the potential for becoming a new method of fat graft in clinical practice.

Background: Long non-coding RNA (lncRNA) regulates the tumorigenesis as well as the development of lung adenocarcinoma (LUAD), which is one of the high-mortality cancers. We explored the influence of lncRNA AC098934 on the malignant biological behavior of LUAD and potential underlying molecular mechanisms. Methods: The expression level of AC098934 in either the LUAD or the normal tissues was identified in the TCGA database. Two AC098934 knockdown siRNAs were infected into cells of LUAD, including A549 as well as H1299 cells, using the lentivirus. Real-time Quantitative polymerase chain reaction (QPCR) helped to determine the knockdown efficiency of AC098934. CCK-8, cell cloning, wound healing combined with transwell assays tested the role of AC098934 in the cell proliferation, migration as well as the invasion. Tumor formation experiment in nude mice subcutaneously confirmed the promoting effect of AC098934 in vivo . In addition, combinations of METTL3 and AC098934, as well as m6A and AC098934 were identified through the RIP assay. Results: Compared to the normal tissues, AC098934 was more highly expressed in LUAD tissues. After AC098934 was knocked down by siRNA, the proliferation, invasion, migration as well as tumorigenesis abilities of both A549 and H1299 cells were reduced. Mechanistically, AC098934 could bind to the m6A antibody and METTL3 protein. METTL3 overexpression promoted the m6A modification on AC098934, thereby increasing the interaction of m6A modification. Conclusion: The highly expressed lncRNA AC098934 in LUAD facilitates the cell proliferation as well as invasion either in vitro or in vivo . METTL3 binds, furthermore, modulates the m6A modification of AC098934. Our research revealed a new molecular mechanism, through which AC098934 promoted the malignant behavior of LUAD tumors under the m6A modification induced by METTL3. This indicates that AC098934 is possible to be a promising biomarker as well as a therapeutic target for the patients with LUAD.

Sarcoma is a rare and an extremely aggressive form of cancer that originates from mesenchymal cells. Pyroptosis exerts a dual effect on tumours by inhibiting tumour cell proliferation while creating a microenvironment suitable for tumour cell development and proliferation. However, the significance of pyroptosis-related gene (PRG) expression in sarcoma has not yet been evaluated. Here, we conduct a retrospective analysis to examine PRG expression in 256 sarcoma samples from The Cancer Genome Atlas database. We identified the PRGs that had a significant correlation with overall patient survival in sarcoma by performing a univariate Cox regression analysis. Subsequently, we conducted a LASSO regression analysis and created a risk model for a six-PRG signature. As indicated from the Kaplan–Meier analysis, this signature revealed a significant difference between high- and low-risk sarcoma patients. A receiver operating characteristic curve analysis confirmed that this signature could predict overall patient survival in sarcoma patients with high sensitivity and specificity. Gene ontology annotation and Kyoto Encyclopaedia of Genes and Genomes pathway enrichment analyses revealed that five independent PRGs were closely associated with increased immune activity. Moreover, we also deciphered that increased number of immune cells infiltrated the tumour microenvironment in sarcoma. In brief, the PRG signature can effectively act as novel prognostic biomarker for sarcoma patients and is associated with the tumour immune microenvironment.

Background: Cutaneous melanoma is cancer that is both malignant and aggressive, with a poor prognosis. Pyroptosis can affect the prognosis of cancer patients by controlling tumor cell growth, migration, and metastasis, as well as is closely related to the tumor immune microenvironment. The significance of pyroptosis-related genes (PRGs) in cutaneous melanoma, however, is unknown. Methods: The training set and external validation sets were cutaneous melanoma samples from The Cancer Genome Atlas (TCGA) database and Gene Expression Omnibus (GEO), respectively. By using univariate Cox regression analysis and selection operator (Lasso) regression model, prognostic genes for overall survival (OS) were found. Candidate genes that were screened were used to calculate risk scores and construct a PRG risk model. The Kaplan Meier curve, time-dependent receiver operating characteristic (ROC) curve, and area under the curve (AUC)were used to assess the functional and prognostic usefulness of gene signatures in the risk model. Furthermore, to speculate on the activity of immune cell infiltration and immune-related pathways in the tumor immune microenvironment and calculate corresponding scores, a single sample gene set enrichment analysis (ssGSEA) was used.Results: An eight PRGs risk signature (AIM2, CASP4, CASP5, CASP8, IL18, NLRC4, NLRP6, PRKACA) were conducted and divided all cutaneous melanoma patients in the TCGA cohort into two groups: Low-risk and High-risk. Both the training and external validation sets showed that patients in the low-risk group showed a significantly higher likelihood of survival than those in the high-risk group (p < 0.001). Except for PRKACA, all the other eight PRGs in our study appeared to be longer survival times for patients. The results of ssGSEA in terms of 16 types of immune cells and the activity of 13 immune-related pathways showed that the High-risk group had lower immune pathway activity and lower levels of immune cell infiltration. In conclusion, the PRG-signature may be a significant predictor of prognosis and may play an essential role in UM patients' tumor immunity.